Heavy Metal Poisoning – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Heavy Metal Poisoning – Pipeline Review, H1 2018’, provides an overview of the Heavy Metal Poisoning pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Heavy Metal Poisoning, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Heavy Metal Poisoning and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Heavy Metal Poisoning

– The report reviews pipeline therapeutics for Heavy Metal Poisoning by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Heavy Metal Poisoning therapeutics and enlists all their major and minor projects

– The report assesses Heavy Metal Poisoning therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Heavy Metal Poisoning

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Heavy Metal Poisoning

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Heavy Metal Poisoning pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

La Jolla Pharmaceutical Company

Medesis Pharma SA

PDX Pharmaceuticals LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Heavy Metal Poisoning Overview

Heavy Metal Poisoning Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Heavy Metal Poisoning Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Heavy Metal Poisoning Companies Involved in Therapeutics Development

La Jolla Pharmaceutical Company

Medesis Pharma SA

PDX Pharmaceuticals LLC

Heavy Metal Poisoning Drug Profiles

deferasirox Drug Profile

Product Description

Mechanism Of Action

R&D Progress

deferoxamine mesylate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emeramide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hinokitiol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJPC-401 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NU-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NU-02 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PDX-003 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Heavy Metal Poisoning Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Zn-DTPA Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heavy Metal Poisoning Dormant Projects

Heavy Metal Poisoning Discontinued Products

Heavy Metal Poisoning Product Development Milestones

Featured News & Press Releases

Mar 30, 2017: SRI International Receives U.S. FDA Clearance for Investigational New Drug Application Evaluating Novel Oral Treatment to Combat Radiation Exposure

Sep 11, 2015: La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Table 1: Number of Products under Development for Heavy Metal Poisoning, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Universities/Institutes, H1 2018

Table 4: Products under Development by Companies, H1 2018

Table 5: Products under Development by Universities/Institutes, H1 2018

Table 6: Number of Products by Stage and Target, H1 2018

Table 7: Number of Products by Stage and Mechanism of Action, H1 2018

Table 8: Number of Products by Stage and Route of Administration, H1 2018

Table 9: Number of Products by Stage and Molecule Type, H1 2018

Table 10: Heavy Metal Poisoning Pipeline by La Jolla Pharmaceutical Company, H1 2018

Table 11: Heavy Metal Poisoning Pipeline by Medesis Pharma SA, H1 2018

Table 12: Heavy Metal Poisoning Pipeline by PDX Pharmaceuticals LLC, H1 2018

Table 13: Heavy Metal Poisoning Dormant Projects, H1 2018

Table 14: Heavy Metal Poisoning Discontinued Products, H1 2018

List of Figures

List of Figures

Figure 1: Number of Products under Development for Heavy Metal Poisoning, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products under Development by Universities/Institutes, H1 2018

Figure 4: Number of Products by Targets, H1 2018

Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 6: Number of Products by Mechanism of Actions, H1 2018

Figure 7: Number of Products by Stage and Mechanism of Actions, H1 2018

Figure 8: Number of Products by Routes of Administration, H1 2018

Figure 9: Number of Products by Stage and Routes of Administration, H1 2018

Figure 10: Number of Products by Top 10 Molecule Types, H1 2018

Figure 11: Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports